M Comabella

Summary

Affiliation: Hospital Universitari Vall d'Hebron
Country: Spain

Publications

  1. ncbi Gender-associated differences of perforin polymorphisms in the susceptibility to multiple sclerosis
    Montse Camiña-Tato
    Centre d esclerosi multiple de Catalunya, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    J Immunol 185:5392-404. 2010
  2. ncbi HLA class I and II alleles and response to treatment with interferon-beta in relapsing-remitting multiple sclerosis
    M Comabella
    Centre d esclerosi multiple de Catalunya, CEM Cat, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Departament de Medicina, Universitat Autonoma de Barcelona corrected Barcelona, Spain
    J Neuroimmunol 210:116-9. 2009
  3. ncbi Immunopathogenesis of multiple sclerosis
    Manuel Comabella
    Centre d esclerosi multiple de Catalunya, CEM Cat, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron HUVH, Barcelona, Spain
    Clin Immunol 142:2-8. 2012
  4. ncbi Identification of a novel risk locus for multiple sclerosis at 13q31.3 by a pooled genome-wide scan of 500,000 single nucleotide polymorphisms
    Manuel Comabella
    Unitat de Neuroimmunologia Clinica, CEM Cat, Hospital Universitari Vall d Hebron, Barcelona, Spain
    PLoS ONE 3:e3490. 2008
  5. ncbi Antiviral immune response in patients with multiple sclerosis and healthy siblings
    M Comabella
    Centre d esclerosi multiple de Catalunya, CEM Cat, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Mult Scler 16:355-8. 2010
  6. ncbi A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis
    M Comabella
    Unitat de Neuroimmunologia Clinica, CEM Cat Edif EUI 2 feminine planta, Hospital Universitari Vall d Hebron, Pg Vall d Hebron 119 129, 08035 Barcelona, Spain
    Brain 132:3353-65. 2009
  7. ncbi Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis
    Manuel Comabella
    Centre d esclerosi multiple de Catalunya, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Edifici Escola d Infermeria 2 feminine planta, Passeig Vall d Hebron 119 129, 08035 Barcelona, Spain
    Arch Neurol 66:972-8. 2009
  8. ncbi Genomics in multiple sclerosis--current state and future directions
    Manuel Comabella
    Unitat de Neuroimmunologia Clinica, Institut de Recerca, Hospital Universitari Vall d Hebron, Barcelona, Spain
    J Neuroimmunol 187:1-8. 2007
  9. ncbi Plasma levels of 15d-PGJ are not altered in multiple sclerosis
    M Comabella
    Unitat de Neuroimmunologia Clinica, CEM Cat, Hospital Universitari Vall d Hebron HUVH, Barcelona, Spain
    Eur J Neurol 16:1197-201. 2009
  10. ncbi Plasma chitotriosidase activity in multiple sclerosis
    M Comabella
    Centre d esclerosi multiple de Catalunya, CEM Cat, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron HUVH, Barcelona, Spain
    Clin Immunol 131:216-22. 2009

Detail Information

Publications62

  1. ncbi Gender-associated differences of perforin polymorphisms in the susceptibility to multiple sclerosis
    Montse Camiña-Tato
    Centre d esclerosi multiple de Catalunya, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    J Immunol 185:5392-404. 2010
    ....
  2. ncbi HLA class I and II alleles and response to treatment with interferon-beta in relapsing-remitting multiple sclerosis
    M Comabella
    Centre d esclerosi multiple de Catalunya, CEM Cat, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Departament de Medicina, Universitat Autonoma de Barcelona corrected Barcelona, Spain
    J Neuroimmunol 210:116-9. 2009
    ..These findings do not support a role of the HLA class I and class II genes as modifiers of the response to IFNbeta...
  3. ncbi Immunopathogenesis of multiple sclerosis
    Manuel Comabella
    Centre d esclerosi multiple de Catalunya, CEM Cat, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron HUVH, Barcelona, Spain
    Clin Immunol 142:2-8. 2012
    ..This review will discuss the key pathogenic steps implicated in the disease and the role of the main cellular populations that drive the immune responses in MS...
  4. ncbi Identification of a novel risk locus for multiple sclerosis at 13q31.3 by a pooled genome-wide scan of 500,000 single nucleotide polymorphisms
    Manuel Comabella
    Unitat de Neuroimmunologia Clinica, CEM Cat, Hospital Universitari Vall d Hebron, Barcelona, Spain
    PLoS ONE 3:e3490. 2008
    ..This region of chromosome 13 has not been previously identified in MS linkage genome screens and represents a novel risk locus for the disease...
  5. ncbi Antiviral immune response in patients with multiple sclerosis and healthy siblings
    M Comabella
    Centre d esclerosi multiple de Catalunya, CEM Cat, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Mult Scler 16:355-8. 2010
    ..We conclude that elevated IgG responses towards EBNA1 are associated with the development of multiple sclerosis...
  6. ncbi A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis
    M Comabella
    Unitat de Neuroimmunologia Clinica, CEM Cat Edif EUI 2 feminine planta, Hospital Universitari Vall d Hebron, Pg Vall d Hebron 119 129, 08035 Barcelona, Spain
    Brain 132:3353-65. 2009
    ....
  7. ncbi Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis
    Manuel Comabella
    Centre d esclerosi multiple de Catalunya, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Edifici Escola d Infermeria 2 feminine planta, Passeig Vall d Hebron 119 129, 08035 Barcelona, Spain
    Arch Neurol 66:972-8. 2009
    ..However, not all patients respond to interferon beta therapy, and to date there is a lack of surrogate markers that reliably correlate with responsiveness to interferon beta therapy in MS...
  8. ncbi Genomics in multiple sclerosis--current state and future directions
    Manuel Comabella
    Unitat de Neuroimmunologia Clinica, Institut de Recerca, Hospital Universitari Vall d Hebron, Barcelona, Spain
    J Neuroimmunol 187:1-8. 2007
    ..In this review, we summarize existing data from different gene expression profiling studies that have been conducted in MS and EAE, discuss potential problems and propose future directions for the use of microarrays in MS...
  9. ncbi Plasma levels of 15d-PGJ are not altered in multiple sclerosis
    M Comabella
    Unitat de Neuroimmunologia Clinica, CEM Cat, Hospital Universitari Vall d Hebron HUVH, Barcelona, Spain
    Eur J Neurol 16:1197-201. 2009
    ..The 15-deoxi delta prostaglandin J(2) (15d-PGJ(2)) is a peroxisome proliferator-activated receptor-gamma agonist with potent anti-inflammatory properties. It has been suggested that 15d-PGJ(2) may modulate multiple sclerosis (MS)...
  10. ncbi Plasma chitotriosidase activity in multiple sclerosis
    M Comabella
    Centre d esclerosi multiple de Catalunya, CEM Cat, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron HUVH, Barcelona, Spain
    Clin Immunol 131:216-22. 2009
    ..Although these findings suggest a role of Chit in MS, our data do not support an association between plasma Chit activity and MS clinical course and clinical response to IFNbeta treatment...
  11. ncbi Induction of serum soluble tumor necrosis factor receptor II (sTNF-RII) and interleukin-1 receptor antagonist (IL-1ra) by interferon beta-1b in patients with progressive multiple sclerosis
    Manuel Comabella
    Unitat de Neuroimmunologia Clinica, Edif EUI 2a planta, Hospital Universitari Vall d Hebron, Pg Vall d Hebron 119 129, 08035, Barcelona, Spain
    J Neurol 255:1136-41. 2008
    ....
  12. ncbi Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis
    Manuel Comabella
    Unitat de Neuroimmunologia Clinica, CEM Cat, Hospital Universitari Vall d Hebron HUVH, Barcelona, Spain
    Clin Immunol 130:145-50. 2009
    ..The early and sustained increase in TIMP-1 levels could be a marker of the response to IFN-b during the first 2 years of treatment...
  13. ncbi Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis
    Manuel Comabella
    Centre d esclerosi multiple de Catalunya, CEM Cat, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron HUVH, Barcelona 08035, Spain
    Brain 133:1082-93. 2010
    ....
  14. ncbi Genetic association of CASP8 polymorphisms with primary progressive multiple sclerosis
    M Camina-Tato
    Centre d esclerosi multiple de Catalunya, CEM Cat, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron HUVH, Departament de Medicina de la Universitat Autònoma de Barcelona, Barcelona, Spain
    J Neuroimmunol 222:70-5. 2010
    ..GG homozygosity for SNP rs2037815 in PPMS patients was associated with a trend towards faster disease progression. These findings point to a role of CASP8 polymorphisms in the MS genetic risk in PPMS patients...
  15. ncbi Measures in the first year of therapy predict the response to interferon beta in MS
    J Rio
    Unitat de Neuroimmunologia Clinica, Hospital Universitario Vall d Hebron, Barcelona, Spain
    Mult Scler 15:848-53. 2009
    ..Hence, the aim of this study was to investigate magnetic resonance imaging (MRI) and clinical predictors of response during the first 12 months of therapy...
  16. ncbi Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?
    M Tintore
    Unit of Clinical Neuroimmunology, Department of Neurology, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
    Neurology 70:1079-83. 2008
    ..To evaluate whether oligoclonal bands (OB) add information to MRI in predicting both a second attack and development of disability in patients with clinically isolated syndromes (CIS)...
  17. ncbi Brainstem lesions in clinically isolated syndromes
    M Tintore
    Unitat de Neuroimmunologia Clinica UNIC, Edif Escola d Infermeria Planta 2, Hospital Universitari Vall d Hebron, Pg Vall d Hebron 119 129, 08035 Barcelona, Spain
    Neurology 75:1933-8. 2010
    ..Number of baseline lesions has been shown to predict future attacks and disability in clinically isolated syndromes (CIS)...
  18. ncbi Do multimodal evoked potentials add information to MRI in clinically isolated syndromes?
    R Pelayo
    Multiple Sclerosis Center of Catalonia, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
    Mult Scler 16:55-61. 2010
    ..However, the utility of MMEPs is limited by the low percentage of CIS patients having the three abnormal at baseline...
  19. ncbi Baseline MRI predicts future attacks and disability in clinically isolated syndromes
    M Tintore
    Unit of Clinical Neuroimmunology Department of Neurology, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Spain
    Neurology 67:968-72. 2006
    ..To determine the relation between baseline MRI and both conversion to multiple sclerosis (MS) and development of disability in a cohort of patients with clinically isolated syndromes (CIS)...
  20. ncbi Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients
    J Rio
    Unitat de Neuroimmunologia Clinica, Hospital Universitario Vall d Hebron, Barcelona, Spain
    Mult Scler 14:479-84. 2008
    ....
  21. ncbi Genetic association between polymorphisms in the BTG1 gene and multiple sclerosis
    M Camina-Tato
    Centre d esclerosi multiple de Catalunya, CEM Cat, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron HUVH, Pg Vall d Hebron, Barcelona, Spain
    J Neuroimmunol 213:142-7. 2009
    ..We identified a risk haplotype associated with relapse-onset MS. These findings support the hypothesis that BTG1 polymorphisms may influence genetic predisposition for MS, especially in relapse-onset MS patients...
  22. ncbi Clinical features of CIS of the brainstem/cerebellum of the kind seen in MS
    Jaume Sastre-Garriga
    Unitat de Neuroimmunologia Clinica, MS Centre of Catalonia, Hospital Universitari Vall d Hebron, EUI 2a planta, Passeig de la Vall d Hebron 119 129, 08035 Barcelona, Spain
    J Neurol 257:742-6. 2010
    ..Results indicate that diplopia, facial sensory symptoms and gait disturbance occur in more than 30% of patients with CISB. Facial sensory symptoms are less associated with conversion to CDMS...
  23. ncbi An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis
    A Horga
    Centre d esclerosi multiple de Catalunya, Barcelona, Espana
    Rev Neurol 52:321-30. 2011
    ..To analyse the safety and effectiveness of natalizumab in the treatment of multiple sclerosis in a real clinical practice setting and according to the approved indications...
  24. ncbi Polyregional and hemispheric syndromes: a study of these uncommon first attacks in a CIS cohort
    R Pelayo
    Department of Neurology, Unit of Clinical Neuroinmunology, Hospital Universitari Vall d Hebron, Universitat Autonoma UAB, Barcelona, Spain
    Mult Scler 13:731-6. 2007
    ..There are differences between several studies in the definition, and, therefore, the prevalence of these so-called atypical CIS. Consensus on the denomination and definition of these syndromes must be reached...
  25. ncbi Value of NMO-IgG determination at the time of presentation as CIS
    C Costa
    Unitat de Neuroimmunologia Clinica UNIC, Centre d Esclerosi Mu ltiple de Catalunya, Vall d Hebron Institut de Recerca, Barcelona, Spain
    Neurology 78:1608-11. 2012
    ..Despite the availability of diagnostic criteria, an overlap between neuromyelitis optica (NMO) and multiple sclerosis (MS) exists, particularly in the early stage of the disease...
  26. ncbi Decreased MMP-9 production in primary progressive multiple sclerosis patients
    J Sastre-Garriga
    Unitat de Neuroimmunologia Clinica, Hospital Vail d Hebron, Barcelona, Espanya
    Mult Scler 10:376-80. 2004
    ..However, data regarding primary progressive (PP) MS is scarce...
  27. ncbi Very early scans for demonstrating dissemination in time in multiple sclerosis
    C Tur
    Clinical Neuroimmunology Unit, Vall d Hebron University Hospital, Barcelona, Spain
    Mult Scler 14:631-5. 2008
    ....
  28. ncbi New diagnostic criteria for multiple sclerosis: application in first demyelinating episode
    M Tintore
    Clinical Neuroimmunology Unit, Department of Neurology, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Neurology 60:27-30. 2003
    ....
  29. ncbi Conversion to multiple sclerosis after a clinically isolated syndrome of the brainstem: cranial magnetic resonance imaging, cerebrospinal fluid and neurophysiological findings
    J Sastre-Garriga
    Unitat de Neuroimmunologia Clinica, Hospital Vall d Hebron, Escola d Infermeria, Barcelona, Espana
    Mult Scler 9:39-43. 2003
    ..The aim of this study was to investigate conversion to MS in patients with CISB...
  30. ncbi Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis
    E Canto
    Centre d esclerosi multiple de Catalunya, CEM Cat, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron HUVH, Universitat Autonoma de Barcelona, Barcelona, Spain
    Mult Scler 18:983-90. 2012
    ..Chitinase 3-like 1 (CHI3L1) is upregulated in a wide variety of inflammatory conditions. Recent studies have pointed to a role of CHI3L1 in multiple sclerosis (MS) pathogenesis...
  31. ncbi Variations in chemokine receptor and cytokine expression during pregnancy in multiple sclerosis patients
    C Lopez
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron HUVH, Barcelona, Spain
    Mult Scler 12:421-7. 2006
    ..These findings indicate immunomodulatory effects of pregnancy on the expression of chemokine receptors and cytokines, which may be related to changes in the clinical disease activity of T cell-mediated autoimmune diseases, such as MS...
  32. ncbi SIGLEC1 and SIGLEC7 expression in circulating monocytes of patients with multiple sclerosis
    S Malhotra
    Centre d esclerosi multiple de Catalunya, Hospital Universitari Vall d Hebron, Spain
    Mult Scler 19:524-31. 2013
    ..Sialic acid binding immunoglobulin-like lectins (Siglecs) are cell surface receptors that recognize sialic acids and may attenuate immune responses and reduce inflammation...
  33. ncbi Cellular immune responses in multiple sclerosis patients treated with interferon-beta
    M F Bustamante
    Centre d esclerosi multiple de Catalunya, CEM Cat, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
    Clin Exp Immunol 171:243-6. 2013
    ..These findings do not support differential cellular immune responses in PBMC at baseline between IFN-β responders and non-responders...
  34. ncbi Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials
    Jordi Rio
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Ann Neurol 52:400-6. 2002
    ....
  35. ncbi Genetic association between polymorphisms in the ADAMTS14 gene and multiple sclerosis
    Robert Goertsches
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron HUVH, Escuela de Enfermeria 2 a planta, Psg Vall d Hebron 119 129, 08035 Barcelona, Spain
    J Neuroimmunol 164:140-7. 2005
    ..No association was detected between different genotypes and disease severity measured by the Multiple Sclerosis Severity Score (MSSS). These findings suggest a potentially important role for the ADAMTS14 gene in predisposition to MS...
  36. ncbi Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis
    J E Martinez-Rodriguez
    Neurology Service, Parc de Salut Mar, IMIM Hospital del Mar Research Institute, Barcelona, Spain
    Clin Immunol 141:348-56. 2011
    ..Our results reveal that IFNβ may promote in responders changes in the NK cell immunophenotype, corresponding to the profile found at early maturation stages of this lymphocyte lineage...
  37. ncbi B cell expression of the inhibitory Fc gamma receptor is unchanged in early MS
    Manuel Comabella
    Centre d esclerosi multiple de Catalunya, CEM Cat, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron HUVH, Barcelona, Spain
    J Neuroimmunol 223:135-7. 2010
    ....
  38. ncbi Is optic neuritis more benign than other first attacks in multiple sclerosis?
    Mar Tintore
    Unit of Clinical Neuroimmunology, Department of Neurology, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Ann Neurol 57:210-5. 2005
    ..Optic neuritis has a smaller risk for conversion to multiple sclerosis. Nevertheless, MRI at baseline, not CIS topography, appears to be the crucial issue at multiple sclerosis presentation...
  39. ncbi Plasma osteopontin levels in multiple sclerosis
    Manuel Comabella
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron HUVH, Escola d Infermeria 2a planta, Pg Vall d Hebron 119 129, 08035 Barcelona, Spain
    J Neuroimmunol 158:231-9. 2005
    ....
  40. ncbi Genetic analysis of SLC11A1 polymorphisms in multiple sclerosis patients
    Manuel Comabella
    Department of Neurology, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Mult Scler 10:618-20. 2004
    ..We found no evidence of association between SLC11A1 polymorphisms and MS susceptibility in the Spanish population...
  41. ncbi Fatigue in progressive multiple sclerosis is associated with low levels of dehydroepiandrosterone
    Nieves Téllez
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, 08035 Barcelona, Spain
    Mult Scler 12:487-94. 2006
    ..Fatigue is one of the most limiting symptoms in multiple sclerosis (MS) and the mechanisms underlying its origin are poorly understood. Our aim was to test whether fatigue in MS is associated with endocrine markers...
  42. ncbi TNF-alpha converting enzyme (TACE) protein expression in different clinical subtypes of multiple sclerosis
    Manuel Comabella
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Escuela de Enfermeria 2a planta, Passeig Vall d Hebron 119 129, 08035 Barcelona, Spain
    J Neurol 253:701-6. 2006
    ..These findings point to different regulatory mechanisms of the TACE-TNF-alpha pathway in the clinical MS subtypes and expand the role of TACE in MS pathogenesis...
  43. ncbi Evidence for association of chromosome 10 open reading frame (C10orf27) gene polymorphisms and multiple sclerosis
    Robert Goertsches
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron HUVH, 08035 Barcelona, Spain
    Mult Scler 14:412-4. 2008
    ..Transcript expression in brain lesions from MS patients was increased. These findings suggest C10orf27 as a candidate gene for MS susceptibility and pathogenesis...
  44. ncbi Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients
    Jordi Rio
    2TM planta EUI, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Ann Neurol 59:344-52. 2006
    ..Early identification of nonresponder patients is crucial to try different therapeutic approaches. We investigated various criteria of treatment response to assess which criterion better identifies patients with a poor response...
  45. ncbi IL28B polymorphisms are not associated with the response to interferon-β in multiple sclerosis
    S Malhotra
    Centre d esclerosi multiple de Catalunya, CEM Cat, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Passeig Vall d Hebron 119 129, Barcelona, Spain
    J Neuroimmunol 239:101-4. 2011
    ..These findings do not support a role of IL28B polymorphisms in the response to IFNβ in MS patients...
  46. ncbi Late-onset metachromatic leukodystrophy clinically presenting as isolated peripheral neuropathy: compound heterozygosity for the IVS2+1G-->A mutation and a newly identified missense mutation (Thr408Ile) in a Spanish family
    M Comabella
    Department of Neurology, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Ann Neurol 50:108-12. 2001
    ..This case indicates that adult metachromatic leukodystrophy should be considered in adult patients with demyelinating peripheral neuropathy of unknown etiology...
  47. ncbi Treatment with interferon-β does not induce anti-nuclear and anti-neuronal serum autoantibodies in multiple sclerosis patients
    M Comabella
    Servei de Neurologia Neuroimmunologia, Centre d esclerosi multiple de Catalunya, CEM Cat, Hospital Universitari Vall d Hebron HUVH, Barcelona, Spain
    J Neuroimmunol 255:102-4. 2013
    ..Thus, pattern of anti-nuclear and anti-neuronal autoantibodies does not predict the response to IFNβ in MS patients...
  48. ncbi Role of tumour necrosis factor (TNF)-α and TNFRSF1A R92Q mutation in the pathogenesis of TNF receptor-associated periodic syndrome and multiple sclerosis
    A Caminero
    Centre d esclerosi multiple de Catalunya, CEM Cat, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Clin Exp Immunol 166:338-45. 2011
    ..An alteration in TNF/TNFRS1A signalling may increase proinflammatory signals; the final clinical phenotype may possibly be determined by other genetic or environmental modifying factors that have not yet been identified...
  49. ncbi A genomic screen of Spanish multiple sclerosis patients reveals multiple loci associated with the disease
    Robert Goertsches
    Neuroimmunology Unit, Hospital Vall d'Hebron, Barcelona, Spain
    J Neuroimmunol 143:124-8. 2003
    ..Our results provide support for the presence of multiple coding regions that contain MS susceptibility genes of small or moderate effect...
  50. ncbi Predicting responders to therapies for multiple sclerosis
    Jordi Rio
    Multiple Sclerosis Centre of Catalonia, Vall d Hebron University Hospital, Passeig Vall d Hebron 119 120, Barcelona, Spain
    Nat Rev Neurol 5:553-60. 2009
    ..We evaluate the roles of clinical measures, MRI and pharmacogenomics in these processes...
  51. ncbi Altered maturation of circulating dendritic cells in primary progressive MS patients
    Cristina Lopez
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, HUVH, Barcelona, Spain
    J Neuroimmunol 175:183-91. 2006
    ..These results suggest an impaired maturation state of DC in PPMS patients, and a beneficial effect of IFN-beta favouring the survival of PDC and promoting a Th2 environment...
  52. ncbi Differential susceptibility to apoptosis of CD4+T cells expressing CCR5 and CXCR3 in patients with MS
    Eva Julià
    Centre d esclerosi multiple de Catalunya, CEM Cat, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron HUVH Universitat Autònoma de Barcelona, Barcelona, Spain
    Clin Immunol 133:364-74. 2009
    ....
  53. ncbi Orchestrating innate immune responses in multiple sclerosis: molecular players
    Marta Fernández
    Centre d esclerosi multiple de Catalunya, CEM Cat, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron HUVH, Barcelona, Spain
    J Neuroimmunol 225:5-12. 2010
    ....
  54. ncbi Association Cluster Detector: a tool for heuristic detection of significance clusters in whole-genome scans
    Tomas Marques-Bonet
    Departament de Ciencies Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain
    Bioinformatics 21:ii180-1. 2005
    ..AVAILABILITY: The tool can be downloaded from http://www.upf.es/cexs/recerca/bioevo/softanddata.htm..
  55. ncbi Deficient Fas expression by CD4+ CCR5+ T cells in multiple sclerosis
    Eva Julià
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
    J Neuroimmunol 180:147-58. 2006
    ..To evaluate whether T cells expressing CCR5 and CXCR3 from multiple sclerosis (MS) patients are more resistant to apoptosis...
  56. ncbi Interferon-beta treatment alters peripheral blood monocytes chemokine production in MS patients
    Manuel Comabella
    Center for Neurologic Diseases, Brigham and Women's Hospital, 77 Avenue Louis Pasteur, HIM 714, Boston, MA 02115, USA
    J Neuroimmunol 126:205-12. 2002
    ..These findings suggest that IFN-beta treatment may have a differential affect on chemokine production by monocytes. Longitudinal studies must be done to confirm these observations...
  57. ncbi mtDNA nt13708A variant increases the risk of multiple sclerosis
    Xinhua Yu
    Section of Immunogenetics, University of Rostock, Rostock, Germany
    PLoS ONE 3:e1530. 2008
    ..Mitochondrial DNA (mtDNA) polymorphism is a possible factor contributing to the maternal parent-of-origin effect in multiple sclerosis (MS) susceptibility...
  58. ncbi Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis
    Esther Byun
    Department of Neurology, University of California, San Francisco, San Francisco, CA 94143 0435, USA
    Arch Neurol 65:337-44. 2008
    ..Recombinant interferon beta therapy is widely used to reduce disease activity in multiple sclerosis (MS). However, up to 50% of patients continue to have relapses and worsening disability despite therapy...
  59. ncbi Transcription-based prediction of response to IFNbeta using supervised computational methods
    Sergio E Baranzini
    Department of Neurology, School of Medicine University of California, San Francisco, USA
    PLoS Biol 3:e2. 2005
    ..Large-scale kinetic reverse-transcription PCR, coupled with advanced data-mining efforts, can effectively reveal preexisting and drug-induced gene expression signatures associated with therapeutic effects...
  60. ncbi Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis
    Rachel Farrell
    J Int Med Res 36:204-8; author reply 208-10. 2008
  61. ncbi Refining genetic associations in multiple sclerosis
    David Booth
    Lancet Neurol 7:567-9. 2008
  62. ncbi Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report
    Hans P Hartung
    Dept of Neurology, Heinrich Heine University, Moorenstrasse 5, 40225, Dusseldorf, Germany
    J Neurol 254:827-37. 2007
    ....